The Impact of Proinflammatory Cytokines and Imiquimod on GLUT1 in HaCaT Keratinocytes - a Potential Anti-Psoriatic Therapeutic Target?

Cell Physiol Biochem. 2023 Mar 22;57(2):54-62. doi: 10.33594/000000615.

Abstract

Background/aims: Glucose metabolism has been proven as an essential process for proliferating keratinocytes, which highlights the importance of glucose transporter-1 (GLUT1) not only in the onset of psoriasis but also in the progression and severity of this inflammation-driven disease. In this study, we attempted to find a connection between proinflammatory cytokines (IL-6, IL-17, IL-23, IL-36, TNF-α), a skin inflammation inducing agent - imiquimod (IMQ) and GLUT1 expression.

Methods: Human keratinocyte HaCaT cell line was incubated with exogenous cytokines: IL-6, IL-17A, IL-23, IL-36, TNF-α at a final concentration of 100 ng/ml, or with 1 µM of IMQ, for 48 h. Following the stimulation, glucose uptake and GLUT1 expression were evaluated. The activity of GLUT1 was measured in the presence of a selective GLUT1 inhibitor, BAY-876. The expression of GLUT1 was examined by immunofluorescence and quantified by qPCR, Western blotting and densitometry.

Results: The results from qPCR analysis showed that the administration of exogenous IL-6, IL-17, IL-23 and IL-36 to HaCaT cells resulted in upregulation of GLUT1-encoding SLC2A1 gene, while TNF-α had no significant effect. The same results were confirmed by immunofluorescence analysis, as the fluorescent intensity of GLUT1 was elevated following cytokine and IMQ stimulation. Western blot and densitometry showed that all examined cytokines, as well as IMQ, increased GLUT1 expression. HaCaT cells displayed an improved intracellular 2-deoxy-D-glucose (2-DG) uptake and GLUT1 activity after stimulation by exogenous cytokines and IMQ. The highest uptake of 2-DG was observed after IL-23 stimulation (1.93x) and the lowest after TNF-α stimulation (1.07x). BAY-876 inhibited the 2-DG uptake compared to control.

Conclusion: Our findings suggest that cytokines and IMQ may play a key role in regulating GLUT1 expression in HaCaT cells. We believe that GLUT1 overexpression could potentially be utilized in the targeted treatment of psoriasis.

Keywords: Cytokines; GLUT1; Glucose transporters; Inflammation; Psoriasis.

MeSH terms

  • Animals
  • Cytokines* / metabolism
  • Disease Models, Animal
  • Glucose Transporter Type 1 / genetics
  • Glucose Transporter Type 1 / metabolism
  • Humans
  • Imiquimod / metabolism
  • Imiquimod / pharmacology
  • Imiquimod / therapeutic use
  • Inflammation / metabolism
  • Interleukin-17 / metabolism
  • Interleukin-23 / metabolism
  • Interleukin-23 / pharmacology
  • Interleukin-23 / therapeutic use
  • Interleukin-6 / metabolism
  • Keratinocytes / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Psoriasis* / drug therapy
  • Skin / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Imiquimod
  • Cytokines
  • Interleukin-17
  • Glucose Transporter Type 1
  • Tumor Necrosis Factor-alpha
  • Interleukin-6
  • Interleukin-23